文献速递骨肌CTMR

双膦酸盐治疗疼痛性骨样骨瘤疗效的开放标签前瞻性观察研究

An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma.
PubMed 文献 · Eur Radiol · 2017-09-07

该前瞻性观察研究纳入23例有经皮或外科消融并发症风险或消融后复发的疼痛性骨样骨瘤患者,每月静脉给予双膦酸盐直至疼痛明显缓解。19例(83%)治疗成功,疼痛视觉模拟评分平均下降76.7%,17例(74%)在平均36个月随访中持续缓解;CT显示瘤巢密度平均增加177.7%(p=0.001),MRI显示骨髓水肿面积平均减少38.4%、信号强度平均减少30.3%(p=0.001和p=0.000)。作者认为双膦酸盐可能加速骨样骨瘤的自发愈合。

要点

  • 双膦酸盐治疗后CT显示瘤巢密度平均增加177.7%(p=0.001),提示瘤巢矿化增加。
  • MRI显示骨髓水肿面积平均减少38.4%、信号强度平均减少30.3%(p=0.001和p=0.000)。
  • 19/23例(83%)疼痛缓解成功,17/23例(74%)在平均36个月随访中持续缓解。

核心结论

  • 23例疼痛性骨样骨瘤患者中17例经双膦酸盐保守治疗获得长期最终成功。
  • 双膦酸盐可能加速骨样骨瘤的自发愈合。

研究设计与样本

  • 前瞻性观察研究,2011年至2014年开展,纳入23例有经皮或外科消融并发症风险或消融后复发的骨样骨瘤患者。
  • 前2例接受帕米膦酸,后21例接受唑来膦酸,每月静脉给药直至疼痛明显缓解,人均输注2.95次。

关键影像表现/征象

  • CT显示瘤巢密度平均增加177.7%(p=0.001)。
  • MRI显示骨髓水肿面积平均减少38.4%(p=0.001),信号强度平均减少30.3%(p=0.000)。

诊断标准与关键数值

  • 双膦酸盐治疗成功定义为疼痛明显缓解,19/23例(83%)成功,其疼痛视觉模拟评分平均下降76.7%。
  • 疼痛缓解效果在17/23例(74%)中持续,平均随访36个月。

临床应用与阅片要点

  • 对有经皮或外科消融并发症风险或消融后复发的疼痛性骨样骨瘤患者,可考虑每月静脉双膦酸盐治疗直至疼痛明显缓解(原文为研究方案描述)。
  • 治疗后影像随访可见瘤巢密度增加和骨髓水肿减少,阅片时需结合临床疼痛缓解情况综合评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess the efficacy of bisphosphonate therapy on bone pain in patients with osteoid osteoma (OO) (main objective), and to describe bisphosphonate-induced changes in nidus mineralisation and regional bone-marrow oedema (BMO).

METHODS: A prospective, observational study was conducted from 2011 to 2014. Patients with risk factors for complications of percutaneous or surgical ablation or recurrence after ablation, were offered once monthly intravenous bisphosphonate treatment until significant pain alleviation was achieved.

RESULTS: We included 23 patients. The first two patients received pamidronate and the next 21 zoledronic acid (mean, 2.95 infusions per patient). Bisphosphonate therapy was successful in 19 patients (83%), whose mean pain visual analogue scale score decreased by 76.7%; this pain-relieving effect persisted in 17 patients (74%) with a mean follow-up time of 36 months. Computed tomography (CT) demonstrated a mean nidus density increase of 177.7% (p = 0.001). By magnetic resonance imaging (MRI), mean decreases were 38.4% for BMO surface area and 30.3% for signal intensity (p = 0.001 and p = 0.000, respectively).

CONCLUSIONS: In 17/23 patients with painful OO managed conservatively with bisphosphonates, long-term final success was achieved. Bisphosphonates may accelerate the spontaneous healing of OO.

KEY POINTS: • 19/23 patients with OO managed with bisphosphonates experienced significant pain relief • Pain relief was sustained in 17/23 patients, mean follow-up of 36 months • CT demonstrated a significant increase in nidus mineralisation • MRI demonstrated a significant decrease in bone marrow oedema • Bisphosphonate therapy may accelerate the spontaneous healing of OO.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bousson V, Leturcq T, Ea HK, et al. An open-label, prospective, observational study of the efficacy of bisphosphonate therapy for painful osteoid osteoma. Eur Radiol. 2017. PMID: 28884296. doi:10.1007/s00330-017-5019-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。